What is MOTS-c?

A 16-amino-acid peptide coded by a short stretch of mitochondrial DNA (in the 12S rRNA gene).

At a glance

What it is
A 16-amino-acid peptide coded by a short stretch of mitochondrial DNA (in the 12S rRNA gene).
Also called
Mitochondrial Open Reading Frame of the 12S rRNA-c
US status
HHS discretionHHS says it does not intend to act against 503A compounding that meets its conditions. That is not an approval.
Evidence
F: None, or contradictedThe FDA found no published study that gave MOTS-c to people: human papers measure the body's own MOTS-c, every effect of giving it comes from mice or cells, and one placebo-controlled trial is recruiting.
Safety signal
No data (unknown ≠ safe)Human use: FDA says the risks "are unknown"Theoretical risk named by FDA or reviewsImmunogenicity, aggregation, peptide-related impurities

Status checked Nov 16, 2026 · Draft policy

What the human evidence looks like

What the human evidence looks like
Kind of studyPeopleWhat was looked at
Observational studies10Measured: muscle MOTS-c after exercise and blood MOTS-c during exercise in 10 young inactive men on a bicycle; this is the body's own MOTS-c, not MOTS-c given as a drug (Reynolds 2021).14
Observational studies30Measured: blood MOTS-c in 30 adults randomized to endurance exercise, resistance exercise or no exercise; this is the body's own MOTS-c, not MOTS-c given as a drug (von Walden 2021).15
Observational studiesNot statedA variant of the MOTS-c gene (m.1382A>C, K14Q) seen in Northeast Asian people was proposed in a letter as one possible factor in Japanese longevity (Fuku 2015), and a later study looked at its link to type 2 diabetes risk (Zempo 2021); this is the body's own MOTS-c, not MOTS-c given as a drug.1617
Registered trials120Measured: insulin sensitivity (Matsuda index) at 12 weeks and adverse events up to 16 weeks in 120 adults aged 18 to 65 with prediabetes and overweight or obesity, given MOTS-c or placebo for 12 weeks with lifestyle counseling (NCT07505745, Phase 2a, randomized, quadruple-blind, sponsor Hudson Biotech; started February 2, 2026, recruiting, no outcome data yet).8

What the human evidence looks like
Kind of studyPeopleWhat was looked at
Registered trials88Registered trial NCT03998514 of CB4211, an analogue, not MOTS-c, against placebo in 88 people (Phase 1a/1b), completed in April 2021; it has posted no outcome data, and we found no paper.918
ReviewsNot statedStudies that gave MOTS-c to people: none published. The FDA searched PubMed, Embase and Cochrane and found none.3

What programs claim, and what has been studied

What programs claim, and what has been studied
What programs claimWhat has been studiedGrade
Regulates mitochondrial energy / metabolismStudied in mice and cells only; no study in people.3F
Improves insulin sensitivity / glucoseStudied in mice; one human trial is recruiting and has no outcome data yet.38F
Weight loss / fat lossStudied in mice on a high-fat diet; no human study.3F
Physical performance / enduranceStudied in mice; the human data are the body's own MOTS-c levels after exercise.314F

What programs claim, and what has been studied
What programs claimWhat has been studiedGrade
Longevity / slows agingOne lifespan study in mice, and an association between a gene variant and longevity in people.316F
Bone health / osteoporosisStudied in rat cells and mice.3F
"Safe", "well tolerated"The FDA says the potential risks in people are unknown.3Contradicted
"FDA-approved peptide"No approved MOTS-c product exists.320Contradicted
"Legal under the HHS policy"The HHS policy is a draft of enforcement discretion, not approval, and covers only MOTS-c acetate by injection.12Unverified

Safety facts

Reports to the FDA

  • The FDA's own searches of FAERS, its adverse event database, up to March 9, 2025 found 0 reports, and an openFDA search (MOTS-C, MOTSC, MOTS C) also returns 0. The FDA notes that 503A compounders "generally do not report" adverse events, and zero reports is not evidence of safety.36
  • USADA lists side effects "among people who claim to purchase MOTS-c online": fast heart rate or palpitations, irritation where it was injected, insomnia, immune reactions and fever. These are unverified reports passed on by USADA, not trial data.11

What the FDA has said

  • The FDA found no human exposure data and no clinical safety studies, and says the "potential safety risks associated with the use of MOTS-c in humans are unknown."3
  • The FDA named three concerns: immunogenicity (an immune response to the peptide, possibly against the body's own MOTS-c), aggregation and peptide-related impurities, "especially when administered by injection routes".35
  • The FDA says MOTS-c is "quickly hydrolyzed in human blood" in a test tube, which "raises the question" whether it reaches active levels in the body.313
  • Compounded drugs are not FDA-approved: the FDA doesn't review their safety, effectiveness or quality before they're sold.222

No data

  • The FDA found no study of either form for acute toxicity, toxicity with repeated use, genotoxicity, effects on development and reproduction, or carcinogenicity.3
  • The FDA found no carcinogenicity study of MOTS-c, and we found no FDA or NIH statement linking MOTS-c to cancer.3
  • We found no data on pregnancy or breastfeeding, children, long-term use, people with cancer, or blends.3

Product quality

  • The FDA found no impurity, aggregate or endotoxin data in the published research and called both forms "not well-characterized". HHS says newer certificates of analysis now report these, and the FDA cites published work that expects the freeze-dried powder to be stable below −20°C.23

Compounded MOTS-c is prepared by a pharmacy to a prescription. It is not FDA-approved: the FDA doesn’t review its safety, effectiveness or quality before it’s sold.

You can report a side effect to the FDA through MedWatch.

What a trustworthy program shows

  • Names the state-licensed 503A pharmacy that fills it (the HHS policy covers 503A pharmacies only)2LegalGood practice
  • Says plainly that no human study of MOTS-c has been published, and that no FDA-approved MOTS-c product exists3Good practice
  • Makes no weight-loss, longevity or performance promises, and does not say "FDA-approved" or "clinically proven"3LegalGood practice
  • Orders lab tests at the start and during treatment, as the prescriber chooses, such as glucose, given the metabolic uses marketedGood practice
  • Warns tested athletes that WADA prohibits MOTS-c at all times11Good practice
  • Does not sell it as "research use only"21Legal
  • Shows the price, renewal, cancellation and refund terms before checkoutGood practice

The conditions of the HHS policy

The policy covers a compounded product only when all of its conditions are met.

  1. Uses a peptide that Appendix A of the HHS policy lists (MOTS-c is no. 4)2Legal
  2. Sells it only as an injection under the skin or into muscle: no oral, nasal, topical or IV MOTS-c2Legal
  3. Has the ingredient characterized, with a certificate of analysis (COA)2Legal
  4. Gets the ingredient from an FDA-registered original manufacturer, and can show a certificate of analysis (COA) with identity, purity, impurity, endotoxin and microbial test findings on request23LegalGood practice
  5. Tells you how to report a side effect (MedWatch), and its pharmacy reports serious adverse events and quality issues to MedWatch2Legal
  6. Labels the product "This is a compounded drug product. Not for resale."2Legal
  7. Sells MOTS-c acetate as a single ingredient, with no blends2Legal
  8. Documents oral bioavailability for any form taken by mouth2Legal
  9. Packs no syringe with it other than an FDA 510(k)-cleared one2Legal
  10. Prescribes only after a licensed prescriber evaluates you, with a valid prescription written for you, and meets all other FD&C Act requirements2Legal

  1. 1.
    HHS notice of availability, FR Doc 2026-22192, 91 FR 68526 (Oct 30, 2026)Tier 1: regulator or registergovinfo.govread Nov 16, 2026↩
  2. 2.
  3. 3.
  4. 4.
    FDA: PCAC meeting page, Jul 23–24, 2026Tier 1: regulator or registerfda.govread Nov 16, 2026↩
  5. 5.
  6. 6.
    openFDA FAERS search for MOTS-C, MOTSC, MOTS C (0 results)Tier 1: regulator or registerapi.fda.govread Nov 16, 2026↩
  7. 7.
    FDA: PCAC questions, Jul 23–24, 2026Tier 1: regulator or registerfda.govread Nov 16, 2026↩
  8. 8.
    ClinicalTrials.gov NCT07505745: MOTS-c in adults with prediabetes and overweight/obesityTier 1: regulator or registerclinicaltrials.govread Nov 16, 2026↩
  9. 9.
    ClinicalTrials.gov NCT03998514: CB4211 Phase 1a/1bTier 1: regulator or registerclinicaltrials.govread Nov 16, 2026↩
  10. 10.
  11. 11.
    USADA: What is the MOTS-c peptide?Tier 1: regulator or registerusada.orgread Nov 16, 2026↩
  12. 12.
    FDA Law Blog (Hyman Phelps): PCAC approves four bulk drug substances (Jul 2026)Tier 3: reference, law firm or pressthefdalawblog.comread Nov 16, 2026↩
  13. 13.
  14. 14.
  15. 15.
  16. 16.
    Fuku N et al. MOTS-c: a player in exceptional longevity? Aging Cell 2015;14(6):921-3Tier 1: regulator or registerpubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
  17. 17.
    Zempo H et al. A pro-diabetogenic mtDNA polymorphism in MOTS-c. Aging 2021;13(2):1692-1717Tier 1: regulator or registerpubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
  18. 18.
    PubMed searches: MOTS-c (total, humans, reviews, trial types, by year), CB4211Tier 1: regulator or registereutils.ncbi.nlm.nih.govread Nov 16, 2026↩
  19. 19.
    ClinicalTrials.gov API search "MOTS-c" (9 records)Tier 1: regulator or registerclinicaltrials.govread Nov 16, 2026
  20. 20.
  21. 21.
    FDA warning letter, www.usapeptide.com (Feb 26, 2025)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
  22. 22.
    FDA: Bulk drug substances used in compounding under section 503ATier 1: regulator or registerfda.govread Nov 16, 2026↩
  23. 23.
  24. 24.
  25. 25.
    DEA: Controlled substances, alphabetical order (12-Nov-26)Tier 1: regulator or registerdeadiversion.usdoj.govread Nov 16, 2026↩
  26. 26.
  27. 27.

We review programs, not peptides. This page reports what has been studied and what US regulators have said, with the source of each fact.

It is not medical advice: a decision about a medication is one to make with a licensed clinician.